The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Study Identifier:
C11-005J
ClinicalTrials.gov Identifier:
NCT01757431
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Eculizumab
Date
May 2012 - Sep 2013
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A
Requirements Information
Sex
Female & Male
Age
N/A - N/A

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Eculizumab
Date
May 2012 - Sep 2013
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A years
Requirements Information

Protocol Summary

Protocol is intended to characterize the overall safety and tolerability of eculizumab in this population.

Trial Locations

Location
Status
Location
Nagano Red Cross Hospital
Nagano, Japan
Status
N/A
Location
Tokyo Medical and Dental University Hospital
Tokyo, Japan
Status
N/A